Serious adverse events · people with surgically‐induced remission in Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · people with surgically‐induced remission in Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · people with surgically‐induced remission in Crohn's disease
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events
1 finding from 1 review
Intervention not reported
Serious adverse events · people with cancer pain
1 finding from 1 review
Serious adverse events · patients with maintenance of medically‐induced remission in Crohn's disease
5‐ASA showed no clear difference in serious adverse events compared with placebo (low certainty).
1 finding from 1 review
Serious adverse events · adults with episodic tension‐type headache
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Serious adverse events · adults with episodic tension‐type headache
1 finding from 1 review
no estimate extracted
Studies not reported
Moderate
Serious adverse events · adults with chronic neuropathic pain
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Intervention not reported
Serious adverse events · Adults with cancer pain
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Serious adverse events ‐ not reported · patients with Shigella dysentery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Other adverse events and complications · people with liver metastases
The review found no eligible studies for this question.
1 finding from 1 review
Withdrawals due to adverse events · people with chronic gout
Febuxostat 40 mg/day showed no clear difference in discontinuations due to adverse events compared with allopurinol (high certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with chronic gout
Febuxostat 80 mg/day showed no clear difference in discontinuations due to adverse events compared with allopurinol (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with chronic gout
Febuxostat 120 mg/day showed no clear difference in discontinuations due to adverse events compared with allopurinol (high certainty).
1 finding from 1 review
Other adverse events clinical criteria · patients with Shigella dysentery
It is very uncertain whether cotrimoxazole changes other adverse events clinical criteria compared with fluoroquinolones (norfloxacin) (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · participants with chronic gout and sUA level > 0.36mmol/L
1 finding from 1 review
Withdrawals due to adverse events · Patients with quiescent ulcerative colitis
It is very uncertain whether probiotics changes withdrawal due to adverse events (52 weeks) compared with 5‐aminosalicylic acid (5‐ASA) (mesalazine) (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events ‐ not reported · people with chronic gout
The review found no eligible studies for this question.
1 finding from 1 review
Adverse events: hypotension · type 1 or type 2 diabetics
Blood pressure intervention/intensive blood pressure intervention may leads to higher adverse events—hypotension compared with placebo/standard blood pressure intervention (low certainty).
1 finding from 1 review